Nanobody CDR Optimization for vWF Binding Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Nanobodies against von Willebrand Factor (vWF) have limitations in terms of affinity, stability, specificity, and immunogenicity, which affect their therapeutic and diagnostic efficacy, particularly in preventing and treating diseases related to platelet-mediated aggregation.
Innovation Solution
Development of improved Nanobodies with enhanced affinity, stability, and specificity, including multispecific formats and humanized variants, specifically designed to target the A1 domain of vWF, with optimized CDR and framework sequences to improve binding properties and reduce cross-reactivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies or Nanobodies against vWF are used, then platelet aggregation can be inhibited, but affinity and binding stability are insufficient
Solution Approach 1:
The patent applies parameter changes by optimizing the CDR sequences (particularly CDR1, CDR2, and CDR3) and framework regions of the Nanobody to enhance binding affinity and stability. Specific amino acid substitutions in the CDR regions modify the binding interface with vWF, improving the strength and stability of the antibody-antigen complex while maintaining specificity for the A1 domain.
2Productivity
If Nanobodies with high affinity for vWF are developed, then therapeutic effectiveness improves, but immunogenicity increases
Solution Approach 1:
The patent applies local quality by humanizing specific regions of the Nanobody while maintaining the non-human CDR sequences that provide high affinity binding. The framework regions are replaced with human sequences to reduce immunogenicity, while the CDR regions (particularly CDR1: YNPMG, CDR2: AISRTGGSTYYPDSVEG, CDR3: AGVRAEDGRVRTLPSEYTF) are preserved to maintain binding functionality. This creates a hybrid structure with locally optimized properties.
3Manufacturing precision
If Nanobodies are designed to target specific vWF conformations, then specificity increases, but cross-reactivity with other proteins increases
Solution Approach 1:
The patent applies parameter changes by optimizing the CDR sequences (particularly CDR1, CDR2, and CDR3) and framework regions of the Nanobody to enhance binding affinity and stability. Specific amino acid substitutions in the CDR regions modify the binding interface with vWF, improving the strength and stability of the antibody-antigen complex while maintaining specificity for the A1 domain.
4Ease of manufacture
If conventional antibody formats are used, then ease of production is maintained, but half-life and in vivo stability are insufficient
Solution Approach 1:
The patent applies universality by designing the Nanobody to serve multiple functions: it binds to vWF with high affinity and specificity, resists proteolytic degradation through optimized framework regions, and can be engineered into various formats (monovalent, bivalent, multispecific) while maintaining a simple production profile. The compact single-domain structure enables versatile applications while preserving ease of production.
Data Source
Figure 1~3
Figure 4~5
Figure 6~7a
AI summary
The present invention relates to improved Nanobodies™ against von Willebrand Factor (vWF), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.